Aldeyra Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2021 Annual Meeting of Stockholders held on June 8, 2021. The filing was submitted on June 9, 2021. Aldeyra Therapeutics, Inc. is a Delaware corporation with common stock (ALDX) traded on The Nasdaq Stock Market, LLC.
Key Financial Metrics
This filing is a Current Report regarding corporate governance matters and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Of the 47,543,812 shares entitled to vote, 35,398,021 shares (approximately 74.5%) were represented, constituting a quorum. The following proposals were approved:
- Proposal 1 (Election of Directors): Stockholders elected Ben Bronstein, M.D., and Nancy Miller-Rich as Class I directors.
- Ben Bronstein, M.D.: 20,405,398 votes For; 6,122,032 votes Withheld.
- Nancy Miller-Rich: 22,783,783 votes For; 3,743,647 votes Withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 35,305,017
- Votes Against: 40,038
- Votes Abstaining: 52,966
- Proposal 3 (Executive Compensation): Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers.
- Votes For: 20,666,431
- Votes Against: 5,734,541
- Votes Abstaining: 126,458
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the voting outcomes of the Annual Meeting.
Key Facts for Investor Verification
- Verify the definitive proxy statement (Schedule 14A) filed on April 14, 2021, for detailed biographies of the elected directors and executive compensation specifics.
- Confirm the tenure of the newly elected Class I directors, which extends until the 2024 annual meeting.
- Note the significant number of broker non-votes (8,870,591) on the director election and executive compensation proposals, indicating shares held by brokers where voting instructions were not received.
- Review the most recent 10-K or 10-Q filings for actual financial performance metrics, as this 8-K contains no financial data.